What happened with SNTI today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Senti Biosciences Holdings, Inc. develops cell therapies for cancer using genetic controls, called gene circuits, intended to help treatment cells attack cancer while sparing healthy cells. Its lead candidate, SENTI-202, is in early clinical development. The company has no approved products and has not generated revenue; selling treatments depends on successful trials and regulatory approval.
Licensing gives it another potential route to income. If BlueRock Therapeutics exercises an option and signs a commercial license, BlueRock would fund development, manufacturing and commercialization, while Senti could receive milestone payments and royalties on sales. These are conditional payments, not established revenue. Celest Therapeutics stopped dosing patients in its SN301A trial after observing dose-limiting toxicities, and Senti does not expect Celest to exercise its license option.
Senti has primarily funded operations through stock sales and sales of manufacturing-related assets, and needs substantial additional financing to continue development. It also has no manufacturing facilities or personnel of its own and relies exclusively on GeneFab for its required SENTI-202 supply, with no backup supplier.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Senti's prospects hinge on clinical validation and funding of its gene-circuit therapies, with BlueRock's options offering a possible source of licensing milestones and royalties.
Nkarta and Senti both engineer donor-derived natural killer cells into ready-to-use CAR-NK treatments, making safety, cell persistence and manufacturing results relevant to both. Watch Nkarta's NKX019 studies, but its lead program treats autoimmune disease rather than Senti's cancer focus.
Fate Therapeutics offers a competing route to Senti's ready-to-use CAR-NK cancer treatments, making immune cells from engineered stem-cell lines rather than using Senti's gene-circuit approach. Ono pays Fate to research and develop solid-tumor candidates, so progress in that collaboration is worth watching alongside Senti's platform.
Allogene Therapeutics competes with Senti in ready-to-use engineered immune-cell cancer treatments, including approaches to acute myeloid leukemia, but uses donor T cells rather than NK cells. Its revenue through December 31, 2025 came exclusively from its licensing agreement with Overland Therapeutics, not treatment sales.
Precigen's PRGN-3006 competes with Senti's logic-gated CAR-NK treatment approach in acute myeloid leukemia, using engineered T cells instead. Precigen has completed enrollment in its PRGN-3006 Phase 1b trial; that program, rather than sales of its approved Papzimeos treatment for adults with recurrent respiratory papillomatosis, is the direct comparison for Senti.
Cullinan Therapeutics' CLN-049 competes with Senti for treating acute myeloid leukemia through the same FLT3 target, but recruits T cells to attack rather than delivering an engineered cell therapy. CLN-049's clinical progress is the relevant signal for Senti, not Cullinan's prospective share of zipalertinib profits from U.S. lung-cancer sales.
Cellectis offers an alternative to Senti's engineered NK-cell cancer treatments through gene-edited, ready-to-use CAR-T cells. Its UCART programs in blood cancers, initially acute lymphoblastic leukemia and non-Hodgkin lymphoma, provide a concrete comparison for the competing T-cell approach.
Caribou Biosciences competes with Senti's engineered CAR-NK cancer therapies through ready-to-use CAR-T treatments for blood cancers. Watch its Phase 1 studies of vispa-cel in relapsed or refractory B-cell non-Hodgkin lymphoma and CB-011 in relapsed or refractory multiple myeloma for progress in that alternative cell-therapy route.
Century Therapeutics' cell persistence, safety and manufacturing results matter to Senti's engineered NK-cell approach, though Century makes immune cells from induced pluripotent stem cells. Watch CNTY-101 in the CARAMEL trial for B-cell-mediated autoimmune diseases as a test of Century's platform, not a direct cancer-treatment comparison.
Artiva Biotherapeutics offers a manufacturing comparison for Senti's gene-circuit-engineered CAR-NK cancer therapies through AlloNK for autoimmune disease and collaborator-funded CAR-NK trials. Artiva reports consistent AlloNK production across batches and donors with GC Cell; whether that consistency holds is the concrete manufacturing signal to watch.
Lyell Immunopharma competes with Senti's logic-gated cancer-cell therapy approach by engineering CAR-T cells to recognize multiple targets. Watch ronde-cel, which can respond to either CD19 or CD20 on B-cell lymphoma through an OR gate, as a concrete test of Lyell's multi-target strategy.
CRISPR Therapeutics competes with Senti's engineered CAR-NK cancer treatments through gene-edited CAR-T candidates for oncology. Its cancer CAR-T progress is the relevant comparison for Senti, rather than its approved CASGEVY treatment for eligible patients with severe sickle cell disease or transfusion-dependent beta thalassemia.
Senti Biosciences Holdings, Inc. earningsThis company
Senti Biosciences has no product-sale revenue, so this report will show whether its cash and financing can sustain SENTI-202 development.
Read cash on hand alongside cash used in operations, and note any new financing. A higher cash balance with slower operating cash use would give Senti more time to advance trials; a falling balance with heavy use and no new funds would point to tighter limits on development. The $22,000 collaboration revenue is too small to change that picture.
Precigen, Inc. earningsPGEN
Precigen's report will show how its PRGN-3006 acute myeloid leukemia program is progressing, revealing where this engineered T-cell alternative stands against Senti Biosciences' SENTI-202.
Watch whether PRGN-3006 advances in its Phase 1b trial and whether Precigen reports new clinical obstacles. Continued progress would mean a T-cell treatment for the same cancer is still moving toward a clinical role, keeping an alternative to SENTI-202 in play; a stall or setback would weaken that near-term competitive signal, but would not prove SENTI-202 works.
